HER2-Low Breast Cancer: Where Are We?

19Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Background: Breast cancer is traditionally classified into three clinical subtypes based on hormone receptor and HER2 status (i.e., luminal-like, HER2-positive, and triple negative). Each subtype has distinct clinical-pathological and molecular characteristics and requires tailored treatments. Recent research efforts have been focusing on a new classification, identifying the so-called "HER2-low"category, including tumors characterized by a low level of HER2 expression (immunohistochemistry score 1+ or 2+ without in situ hybridization amplification). Emerging evidence shows that patients with HER2-low tumors can derive benefit from selected anti-HER2 therapies. This represents a major advancement in the field of breast oncology, where a broader proportion of patients with breast cancer can ultimately benefit from new effective targeted treatment strategies. Summary: The antibody-drug conjugate trastuzumab deruxtecan has proven impressive efficacy in patients with HER2-low breast cancer, and several other drugs are currently under investigation in this subset of patients. Additional investigation is needed to address open issues that exist in this field, including appropriate pathological assessment of HER2-low status, clarification of its prognostic implications, and global access to newly approved drugs. Key Message: Our review aims to summarize the available evidence regarding HER2-low breast cancer, illustrating the current challenges that are being addressed and the future perspectives in this exciting new field.

References Powered by Scopus

Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011

3192Citations
N/AReaders
Get full text

Breast Cancer Treatment: A Review

3107Citations
N/AReaders
Get full text

Breast cancer

1788Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis

39Citations
N/AReaders
Get full text

Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis

35Citations
N/AReaders
Get full text

Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Molinelli, C., Jacobs, F., Marchiò, C., Pitto, F., Cosso, M., Spinaci, S., … Lambertini, M. (2022, December 1). HER2-Low Breast Cancer: Where Are We? Breast Care. S. Karger AG. https://doi.org/10.1159/000527391

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

33%

Researcher 3

33%

Professor / Associate Prof. 2

22%

Lecturer / Post doc 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

77%

Biochemistry, Genetics and Molecular Bi... 1

8%

Physics and Astronomy 1

8%

Pharmacology, Toxicology and Pharmaceut... 1

8%

Save time finding and organizing research with Mendeley

Sign up for free